Interleukin-17 contributes to cardiovascular diseases

Interleukin (IL)-17 (also known as IL-17A), as the signature cytokine of the newly described T helper 17 (Th17) cell population, is the founding member of a new subclass of cytokines that have highly proinflammatory properties. Recently there is accumulating evidence that stipulates the involvement of IL-17 in the pathogenesis of cardiovascular diseases via amplifying the inflammation induced by other cytokines in synergistic interactions. The present review provides a summary of the potential roles of IL-17 in the context derived from both animal models and clinical settings in cardiovascular diseases, and perspectives for IL-17-targeted cytokine therapy.

[1]  K. Qing,et al.  Distinct different expression of Th17 and Th9 cells in coxsackie virus B3-induced mice viral myocarditis , 2011, Virology Journal.

[2]  C. Schindler,et al.  IL-6 and the acute phase response in murine atherosclerosis. , 2004, Atherosclerosis.

[3]  Jun Yang,et al.  The cardioprotective effect of fluvastatin on ischemic injury via down-regulation of toll-like receptor 4 , 2011, Molecular Biology Reports.

[4]  V. Tuohy,et al.  The adaptor Act1 is required for interleukin 17–dependent signaling associated with autoimmune and inflammatory disease , 2007, Nature Immunology.

[5]  K. Qing,et al.  Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of coxsackievirus b3-induced viral myocarditis reduces myocardium inflammation , 2011, Virology Journal.

[6]  C. Dong,et al.  Act1 Adaptor Protein Is an Immediate and Essential Signaling Component of Interleukin-17 Receptor* , 2006, Journal of Biological Chemistry.

[7]  K. Ley,et al.  Interleukin 17 in vascular inflammation. , 2010, Cytokine & growth factor reviews.

[8]  J. Flynn,et al.  IL-17 Production Is Dominated by γδ T Cells rather than CD4 T Cells during Mycobacterium tuberculosis Infection1 , 2006, The Journal of Immunology.

[9]  Kenneth M. Murphy,et al.  Decision making in the immune system: The lineage decisions of helper T cells , 2002, Nature Reviews Immunology.

[10]  F. Sallusto,et al.  Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. , 2007, Nature immunology.

[11]  Jing Yuan,et al.  The Th17/Treg functional imbalance during atherogenesis in ApoE(-/-) mice. , 2010, Cytokine.

[12]  M. Kawaguchi,et al.  Modulation of bronchial epithelial cells by IL-17. , 2001, The Journal of allergy and clinical immunology.

[13]  Shuang Chen,et al.  IL-17A Is Proatherogenic in High-Fat Diet-Induced and Chlamydia pneumoniae Infection-Accelerated Atherosclerosis in Mice , 2010, The Journal of Immunology.

[14]  S. Gaffen,et al.  Structure-function relationships in the IL-17 receptor: implications for signal transduction and therapy. , 2008, Cytokine.

[15]  Y. Iwakura,et al.  Interleukin-17A Is Dispensable for Myocarditis but Essential for the Progression to Dilated Cardiomyopathy , 2010, Circulation research.

[16]  Wei Liu,et al.  IL-17 induces myocardial fibrosis and enhances RANKL/OPG and MMP/TIMP signaling in isoproterenol-induced heart failure. , 2009, Experimental and molecular pathology.

[17]  R. Coffman,et al.  Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. , 1986, Journal of immunology.

[18]  S. Romagnani,et al.  The Th1/Th2 paradigm. , 1997, Immunology today.

[19]  A. Andoh,et al.  Increased expression of interleukin 17 in inflammatory bowel disease , 2003, Gut.

[20]  L. Cosmi,et al.  Phenotypic and functional features of human Th17 cells , 2007, The Journal of experimental medicine.

[21]  Kenneth M. Murphy,et al.  Functional diversity of helper T lymphocytes , 1996, Nature.

[22]  C. Uyttenhove,et al.  Loss of SOCS3 expression in T cells reveals a regulatory role for interleukin-17 in atherosclerosis , 2009, The Journal of experimental medicine.

[23]  P. Teeling,et al.  Differential expression of interleukin‐17 family cytokines in intact and complicated human atherosclerotic plaques , 2010, The Journal of pathology.

[24]  F. Sallusto,et al.  Interleukins 1β and 6 but not transforming growth factor-β are essential for the differentiation of interleukin 17–producing human T helper cells , 2007, Nature Immunology.

[25]  V. Kuchroo,et al.  TH-17 cells in the circle of immunity and autoimmunity , 2007, Nature Immunology.

[26]  S. Hong,et al.  PTEN Down-Regulates IL-17 Expression in a Murine Model of Toluene Diisocyanate-Induced Airway Disease1 , 2007, The Journal of Immunology.

[27]  Ying Wang,et al.  A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17 , 2005, Nature Immunology.

[28]  H. Rabb,et al.  Lymphocytes and ischemia-reperfusion injury. , 2009, Transplantation reviews.

[29]  Zhijian Yang,et al.  A polymorphism in the visfatin gene promoter is related to decreased plasma levels of inflammatory markers in patients with coronary artery disease , 2011, Molecular Biology Reports.

[30]  G. Eberl,et al.  Critical role of ROR-γt in a new thymic pathway leading to IL-17-producing invariant NKT cell differentiation , 2008, Proceedings of the National Academy of Sciences.

[31]  Wei Liu,et al.  Adenovirus‐mediated ICOSIg gene transfer alleviates cardiac remodeling in experimental autoimmune myocarditis , 2008, Immunology and cell biology.

[32]  A. Becker,et al.  Atherosclerotic lesions in humans. In situ immunophenotypic analysis suggesting an immune mediated response. , 1989, Laboratory investigation; a journal of technical methods and pathology.

[33]  K. Ley,et al.  Blockade of Interleukin-17A Results in Reduced Atherosclerosis in Apolipoprotein E–Deficient Mice , 2010, Circulation.

[34]  Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of coxsackievirus b3-induced viral myocarditis reduces myocardium inflammation , 2011 .

[35]  E. Bettelli,et al.  IL-17 producing CD4+ T cells mediate accelerated ischemia/reperfusion-induced injury in autoimmunity-prone mice. , 2009, Clinical immunology.

[36]  A. Lindén,et al.  Interleukin-17 family members and inflammation. , 2004, Immunity.

[37]  Peter Libby,et al.  Innate and Adaptive Immunity in the Pathogenesis of Atherosclerosis , 2002, Circulation research.

[38]  M. Entman,et al.  The inflammatory response in myocardial infarction. , 2002, Cardiovascular research.

[39]  W. Fanslow,et al.  Complete nucleotide sequence of the mouse CTLA8 gene. , 1996, Gene.

[40]  Peter Libby,et al.  The immune response in atherosclerosis: a double-edged sword , 2006, Nature Reviews Immunology.

[41]  Chun-xia Shi,et al.  Attenuation of ischemia–reperfusion injury by sevoflurane postconditioning involves protein kinase B and glycogen synthase kinase 3 beta activation in isolated rat hearts , 2010, Molecular Biology Reports.

[42]  Scott R. Presnell,et al.  Identification of the IL-17 Receptor Related Molecule IL-17RC as the Receptor for IL-17F , 2007, The Journal of Immunology.

[43]  D. Jarrossay,et al.  Surface phenotype and antigenic specificity of human interleukin 17–producing T helper memory cells , 2007, Nature Immunology.

[44]  J. Derry,et al.  Cutting Edge: Interleukin 17 Signals through a Heteromeric Receptor Complex , 2006, The Journal of Immunology.

[45]  S. Gaffen.  An overview of IL-17 function and signaling. , 2008, Cytokine.

[46]  R. D. Hatton,et al.  Interleukin 17–producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages , 2005, Nature Immunology.

[47]  D. Ye,et al.  Increased serum interleukin 17 in patients with systemic lupus erythematosus , 2009, Molecular Biology Reports.

[48]  L. Garrett-Sinha,et al.  IL-17 and the Th17 lineage in systemic lupus erythematosus , 2008, Current opinion in rheumatology.

[49]  William Wijns,et al.  ACUTE MYOCARDIAL INFARCTION: REPERFUSION TREATMENT , 2002, Heart.

[50]  Chen Dong,et al.  TH17 cells in development: an updated view of their molecular identity and genetic programming , 2008, Nature Reviews Immunology.

[51]  Feng-Lai YuanXia.  Type 17 T-helper cells might be a promising therapeutic target for osteoporosis , 2012 .

[52]  K. Książek,et al.  Interleukin-17: a mediator of inflammatory responses , 2004, Cellular and Molecular Life Sciences CMLS.

[53]  C. Dong,et al.  Regulatory mechanisms of helper T cell differentiation: new lessons learned from interleukin 17 family cytokines. , 2008, Pharmacology & therapeutics.

[54]  Graham M Lord,et al.  The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease , 2007, Clinical and experimental immunology.

[55]  Liyong Pu,et al.  In vitro induced CD4(+)CD25(+)Foxp3(+) Tregs attenuate hepatic ischemia-reperfusion injury. , 2009, International immunopharmacology.

[56]  H. Rabb,et al.  Ischemia-reperfusion and immediate T cell responses. , 2007, Cellular immunology.

[57]  J. Quach,et al.  Interleukin-17-induced Gene Expression in Articular Chondrocytes Is Associated with Activation of Mitogen-activated Protein Kinases and NF-κB* , 1998, The Journal of Biological Chemistry.

[58]  K. Murphy,et al.  Th17: an effector CD4 T cell lineage with regulatory T cell ties. , 2006, Immunity.

[59]  Xiaoxia Li.  Act1 modulates autoimmunity through its dual functions in CD40L/BAFF and IL-17 signaling. , 2008, Cytokine.

[60]  D. Böckler,et al.  Inhibition of IL-17A Attenuates Atherosclerotic Lesion Development in ApoE-Deficient Mice1 , 2009, The Journal of Immunology.

[61]  J. Pober,et al.  Interleukin-17 and Interferon-γ Are Produced Concomitantly by Human Coronary Artery–Infiltrating T Cells and Act Synergistically on Vascular Smooth Muscle Cells , 2009, Circulation.

[62]  F. Denizot,et al.  CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpesvirus saimiri gene. , 1993, Journal of immunology.

[63]  Yong Chen,et al.  The Th17/Treg imbalance in patients with acute coronary syndrome. , 2008, Clinical immunology.

[64]  Xiang Cheng,et al.  Th17 Cells Contribute to Viral Replication in Coxsackievirus B3-Induced Acute Viral Myocarditis , 2010, The Journal of Immunology.

[65]  E. Lubberts,et al.  IL-17/Th17 targeting: on the road to prevent chronic destructive arthritis? , 2008, Cytokine.

[66]  Yan-Lin Wang,et al.  Adenosine postconditioning protects against myocardial ischemia–reperfusion injury though modulate production of TNF-α and prevents activation of transcription factor NF-kappaB , 2010, Molecular Biology Reports.

[67]  Q. Hamid,et al.  IL-17 is increased in asthmatic airways and induces human bronchial fibroblasts to produce cytokines. , 2001, The Journal of allergy and clinical immunology.

[68]  K. Yamaguchi,et al.  Requirement of Tumor Necrosis Factor Receptor–Associated Factor (Traf)6 in Interleukin 17 Signal Transduction , 2000, The Journal of experimental medicine.

[69]  M. Seldin,et al.  Herpesvirus Saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor. , 1995, Immunity.

[70]  T. Paavonen,et al.  Infiltrates of activated mast cells at the site of coronary atheromatous erosion or rupture in myocardial infarction. , 1995, Circulation.